0.95Open0.90Pre Close8 Volume396 Open Interest17.50Strike Price735.00Turnover82.43%IV12.44%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.85Extrinsic Value100Contract SizeAmericanOptions Type0.4068Delta0.1194Gamma19.20Leverage Ratio-0.0307Theta0.0034Rho7.81Eff Leverage0.0153Vega
Grail Stock Discussion
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet